stockportfolio.pro
Stocks / AVNS vs COLL
AVNS vs COLL
Avanos Medical, Inc. and Collegium Pharmaceutical, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Avanos Medical, Inc. (AVNS) | Collegium Pharmaceutical, Inc. (COLL) | |
|---|---|---|
| Market cap | $1.2B | $1.1B |
| Revenue (latest FY) | $701.20M | $780.57M |
| Net income (latest FY) | $-72.90M | $62.87M |
| Revenue growth (5y CAGR) | -0.4% | 20.3% |
| Net margin | -10.4% | 8.1% |
| Return on equity | -9.4% | 20.8% |
| P/E ratio | — | 16.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 5 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AVNS — free Open COLL — freeFrequently asked questions
Which is bigger, AVNS or COLL?
Avanos Medical, Inc. is larger by market capitalization — $1.2B versus $1.1B.
Which grows faster, AVNS or COLL?
Over the last five fiscal years, Collegium Pharmaceutical, Inc. grew revenue faster — 20.3%/yr versus -0.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.